Medication info
Tapagazine 5 mg (Dapaglifozen Propanediol Hydrate)

Tapagazine 5 mg (Dapaglifozen Propanediol Hydrate)

Prescription medicationTabletOral
Ingredient · strength
Dapagliflozin Propanediol Hydrate›6.15mg / 1 tablet
Manufacturer / importer
Daehwa Pharmaceutical Co., Ltd.
Appearance
Yellow, round, biconvex film-coated tablets
Packaging
2 blisters/box [(14 tablets/blister) × 2]
Approval status
Active

MFDS item code 202300371 · Approved 2023.01.30 · Insurance code 645605800

Summary

Main use
Improvement of blood glucose control in type 2 diabetes mellitus; prevention of worsening chronic heart failure and chronic kidney disease
Who takes it
Adults · Children
Adult dose
Type 2 diabetes mellitus Monotherapy and add-on combination therapy The recommended dose of this medicine is 10mg once daily for monotherapy and add-on combination therapy with other glucose-lowering agents, including insulin. When this medicine is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. Initial combination therapy For patients with no previous experience with antidiabetic drug therapy who are receiving this medicine in combination with metformin, the recommended initial dose is 5mg once daily or 10mg once daily. Chronic heart failure and chronic kidney disease The recommended dose of this medicine is 10 mg once daily. Special populations Renal impairment - eGFR below 45 mL/min/1.73m2: Use of this medicine to improve glycemic control is not recommended. - eGFR below 25 mL/min/1.73m2: Initiation of this medicine is not recommended in patients with chronic heart failure and chronic kidney disease. - Patients on dialysis: Do not administer this medicine. Hepatic impairment No dose adjustment is necessary in patients with mild or moderate hepatic impairment. For patients with severe hepatic impairment, a starting dose of 5 mg is recommended. If well tolerated, this dose may be increased to 10mg. Older adults (≥ 65 years) Dose adjustment based on age is not recommended. Method of administration This medicine may be administered orally once daily at any time of day, with or without food. The tablet should be swallowed whole.
Child dose
The efficacy and safety of dapagliflozin in children under 18 years of age have not been established. No relevant data are available.

Ingredients

Manufacturer
Daehwa Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of blood glucose control in type 2 diabetes mellitus; prevention of worsening chronic heart failure and chronic kidney disease

  • Type 2 diabetes
  • blood sugar control disorders
  • cardiovascular diseases
  • cardiovascular risk factors
  • chronic heart failure
  • heart failure
  • chronic kidney disease
  • estimated glomerular filtration rate decline
  • end-stage kidney disease
View approved original text

This medication is an adjunct therapy used in conjunction with diet and exercise to help control blood sugar levels in patients with type 2 diabetes. In patients whose blood sugar is not well controlled, it may be administered alone or in combination with other medications. Additionally, it aids patients with chronic heart failure in reducing the risk of death or hospitalization due to cardiovascular disease, and it is used alongside other heart failure medications. For patients with chronic kidney disease, this medication contributes to reducing the risk of kidney function decline and cardiovascular-related mortality and is used in conjunction with other kidney disease treatments. Thus, this medication plays an significant role in the treatment of diabetes, chronic heart failure, and chronic kidney disease, assisting in the improvement of patients' health.

How to take

Adult dose

Type 2 diabetes mellitus Monotherapy and add-on combination therapy The recommended dose of this medicine is 10mg once daily for monotherapy and add-on combination therapy with other glucose-lowering agents, including insulin. When this medicine is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. Initial combination therapy For patients with no previous experience with antidiabetic drug therapy who are receiving this medicine in combination with metformin, the recommended initial dose is 5mg once daily or 10mg once daily. Chronic heart failure and chronic kidney disease The recommended dose of this medicine is 10 mg once daily. Special populations Renal impairment - eGFR below 45 mL/min/1.73m2: Use of this medicine to improve glycemic control is not recommended. - eGFR below 25 mL/min/1.73m2: Initiation of this medicine is not recommended in patients with chronic heart failure and chronic kidney disease. - Patients on dialysis: Do not administer this medicine. Hepatic impairment No dose adjustment is necessary in patients with mild or moderate hepatic impairment. For patients with severe hepatic impairment, a starting dose of 5 mg is recommended. If well tolerated, this dose may be increased to 10mg. Older adults (≥ 65 years) Dose adjustment based on age is not recommended. Method of administration This medicine may be administered orally once daily at any time of day, with or without food. The tablet should be swallowed whole.

Child dose

The efficacy and safety of dapagliflozin in children under 18 years of age have not been established. No relevant data are available.

Precautions

This medication should not be used by patients with allergies to the active ingredient or additives, patients with type 1 diabetes, patients with diabetic ketoacidosis, patients with lactose intolerance or related genetic disorders, and patients undergoing dialysis. It should be administered cautiously to patients with decreased fluid volume or renal impairment, and blood pressure and renal function should be closely monitored before and after administration. This medication may cause side effects such as genital infections, urinary tract infections, hypoglycemia, decreased fluid volume, diabetic ketoacidosis, and renal function abnormalities, so if any unusual symptoms occur, one should immediately consult a healthcare professional. Particularly, elderly patients or those with impaired kidney function are at higher risk for side effects and require additional caution. Women who are pregnant or breastfeeding are advised not to use this medication, and treatment should be discontinued upon confirmation of pregnancy. This medication may increase the risk of hypoglycemia when used with drugs that can cause hypoglycemia, such as insulin or sulfonylureas, thus dosage adjustments may be necessary for these medications. Also, it should be noted that glucose may be detected in urine tests while taking this medication. In case of overdose, there is no specific antidote available, so symptomatic treatment is required, and it is known that it cannot be removed by dialysis. This medication does not significantly affect driving or machine operation ability; however, caution is necessary when used in combination with medications that pose a risk of hypoglycemia. Finally, its use is not recommended in children due to insufficient safety and efficacy data.

Side effects

Vulvovaginitis, balanitis and related genital infections, urinary tract infections, fungal infections, perineal necrosis, hypoglycemia, decreased fluid volume, polydipsia, diabetic ketoacidosis, dizziness, constipation, dry mouth, back pain, dysuria, polyuria, nocturia, vulvar itching, genital itching, increased hematocrit, early treatment reduction in creatinine clearance, dyslipidemia, early treatment increase in blood creatinine, elevated blood urea, weight loss, acute pyelonephritis, rash, angioedema, asthenia, pain, keratitis, chronic obstructive pulmonary disease, hemoptysis, cerebral hemorrhage, peripheral artery occlusion, angina pectoris, myocardial infarction, bile duct stones, cholangitis, alcoholic cirrhosis, depression, suicide attempt, gastric adenocarcinoma, anaphylactic reaction, chest pain, paresthesia, cerebral infarction, nerve compression, urosepsis, pyelonephritis, hyperglycemia, sensory loss, headache, nasopharyngitis, upper respiratory tract infection, edema, fever, foreign body sensation, facial edema, facial pain, warmth, flu-like symptoms, vaginal discharge, menstrual irregularities, itching, hives, cold sweat, arthralgia, musculoskeletal pain, limb pain, muscular weakness, myalgia, osteoarthritis, ligament sprain, diabetic retinopathy, cough, dyspnea, orthostatic hypotension, palpitations, insomnia, fatty liver, gallbladder polyps, tinnitus

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to protect it from air and moisture. Moreover, it is best to keep the medication at room temperature between 1 to 30 degrees Celsius. Avoid storing it in excessively hot or cold places.

Appearance and packaging

Appearance

Yellow, round, biconvex film-coated tablets

Package unit

2 blisters/box [(14 tablets/blister) × 2]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.